干扰素β-1a生物类似药(Cinnagen)(Interferon beta-1a biosimilar high-dose(Cinnagen)) - 药物靶点：IFNAR_在研适应症：多发性硬化症_专利_临床

概要

基本信息

药物类型

干扰素、生物类似药

别名

Rec Hu-IFN beta 1a-44 microgram、ReciGen

靶点

IFNAR

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)、免疫调节剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 12364

当前序列信息引自: *****

关联

1

项与干扰素β-1a生物类似药(Cinnagen) 相关的临床试验

IRCT2013073114234N1 / Completed临床2/3期IIT

The assessment of effect of Cinnovex, Rebif and Betaferon on serum level of brain-derived neurotrophic factor in multiple sclerosis patients referring to neurology department of Ahwaz Golestan hospital.

开始日期2012-06-21

申办/合作机构-

100 项与干扰素β-1a生物类似药(Cinnagen) 相关的临床结果

登录后查看更多信息

100 项与干扰素β-1a生物类似药(Cinnagen) 相关的转化医学

登录后查看更多信息

100 项与干扰素β-1a生物类似药(Cinnagen) 相关的专利（医药）

登录后查看更多信息

4

项与干扰素β-1a生物类似药(Cinnagen) 相关的文献（医药）

2023-12-31·Journal of pharmaceutical policy and practice

Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study

Article

作者: Roshani, Daem ; Rasouli, Mohammad Aziz ; Moradi, Ghobad ; Moradi, Yousef ; Mohsenpour, Behzad ; Ghaderi, Ebrahim ; Asadi, Jalal

OBJECTIVES:

Different drugs have different effects on the prognosis of patients with COVID-19. This study aimed to evaluate the effect of different drug regimens on patients with COVID-19, hospitalized in Sanandaj city.

METHODS:

In this retrospective cohort study, 660 patients with COVID-19, hospitalized in the Tohid, Kowsar and Besat hospitals located Sanandaj (Kurdistan Province, Iran) were studied from February 2020 to February 2021 with clinical symptoms and positive test results.

RESULTS:

The results of multivariate regression analysis showed the days of hospitalization for patients who had received the drug regimen 2 (Interferons (ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) was 1.92 times higher than those who had received the drug regimen 1 (hydroxychloroquine group or a combination of chloroquine and azithromycin) while a significant association was observed (OR = 1.92, 95% CI: 1.16-3.16, P = 0.011). Also, the hospitalization in ICU was longer in patients treated by the drug regimen 2 (Interferons (ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) (OR = 4.63, 95% CI: 1.80-11.82, P = 0.001), however, drug regimens did not show a significant effect on mortality and use of ventilator in patients (P > 0.05).

CONCLUSION:

The study results showed the drug regimens 2 and 5 increased the days of hospitalization and hospitalization in ICU, respectively, while the other drug regimens had no significant effect on mortality and use a ventilator in the studied patients and none of the drug regimens had an effect on reducing mortality compared to other ones.

2022-12-01·Health economics review4区 · 经济学

Economic burden of multiple sclerosis: a cross-sectional study in Iran

4区 · 经济学

ArticleOA

作者: Izadi, Sadegh ; Rezaee, Mehdi ; Keshavarz, Khosro ; Ravangard, Ramin ; Jafari, Abdosaleh

Abstract:

Background:

Multiple Sclerosis (MS) is a chronic debilitating disease that imposes a heavy socioeconomic burden on societies. This study aimed to determine the economic burden of MS on patients using the first (CinnoVex and ReciGen) and second (Fingolimod and Natalizumab) drug therapy lines.

Methods:

This cost of illness study was an economic evaluation carried out as cross-sectional research in 2019 in southern Iran. A total of 259 patients were enrolled in two lines of drug therapy (178 patients in the first line and 81 ones in the second). The prevalence-based approach and the bottom-up approach were used to collect cost information and to calculate the costs from the societal perspective, respectively. The human capital approach was applied to calculate indirect costs. To collect the required data a researcher-made data collection form was utilized. The data were obtained using the information available in the patients’ medical records and insurance invoices as well as their self-reports or that of their companions.

Results:

The results showed that the annual costs of MS in the first and second lines of drug therapy per patient were $ 1919 and $ 4082 purchasing power parity (PPP), respectively, and in total, $ 2721 PPP in 2019. The highest mean costs in both lines were those of direct medical costs, of which purchasing the main medicines in both lines accounted for the highest.

Conclusion:

Considering the findings of this study and in order to reduce the burden of the disease, the following suggestions are presented: providing necessary facilities for the production of MS drugs in the country; proper and equitable distribution of neurologists; expanding the provision of home care services; and using the technologies related to the Internet, including WhatsApp, to follow up the MS patients’ treatment.

2018-09-01·International immunopharmacology2区 · 医学

Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability

2区 · 医学

Article

作者: Farhad Bahraminia ; Arman Ajami ; Fereshteh Ashtari ; Nabiollah Asghari ; Mahdieh Shokrollahi Barough ; Parviz Kokhaei ; Ghasem Mosayebi ; Mehdi Sadat Akhavi ; Naser Kokhaei ; Majid Mirmohammadkhani

INTRODUCTION:

Human recombinant interferon beta (IFN-β) is one of the first line treatments for Relapsing-Remitting Multiple Sclerosis (RRMS). However, the production of neutralizing antibodies (NAb) can impair its function. The aim of this study was to investigate the production of neutralizing antibodies against Rebif® and ReciGen® (two brands of IFN-β-1a) and to evaluate its correlation with Expanded Disability Status Scale (EDSS).

MATERIALS AND METHODS:

Serum samples of 71 RRMS patients (34 in ReciGen®, 37 in Rebif® group) were collected. Neutralizing antibody was measured by Myxo-virus resistance protein A (MxA) assay using A549 cell line. The MxA concentration was measured by enzyme-linked immunosorbent assay (ELISA) kit.

RESULTS:

The median period of treatment with IFN-β-1a was 18 months in ReciGen® and 24 months in Rebif® arms. The percentage of patients with positive titer of neutralizing antibody (NAb+) had no statistically significant difference between groups (P = 0.6). In both ReciGen® and Rebif® groups, the increase in EDSS score was significantly higher in NAb+ patients compared to NAb- patients (p ≤ 0.05). The duration of using ReciGen® or Rebif® for >24 months was influential in the NAb positivity (OR = 3.78).

CONCLUSION:

Receiving interferon beta-1a for >24 months is correlated with higher possibility of NAb production. The type of IFN-β used in the study had no significant impact on NAb positivity. In addition, both groups had comparable EDSS score changes, and NAb status of patients was correlated with their EDSS score.

100 项与干扰素β-1a生物类似药(Cinnagen) 相关的药物交易

登录后查看更多信息